Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a company specializing in percutaneous vessel closure technology.
Vivasure's PerQseal Elite system offers innovative solutions for structural heart and endovascular procedures.
The acquisition involves an upfront cash payment of \\u20ac100 million with additional contingent consideration based on sales growth and milestones.
Haemonetics Corporation's acquisition of Vivasure Medical Limited marks a strategic move to enhance its closure device technologies and strengthen its market position in innovative medical solutions. The deal includes an initial cash payment of \\u20ac100 million, with further payments linked to performance metrics like sales growth and milestones. Through this transaction, Haemonetics aims to expand its product portfolio and leverage Vivasure's innovative PerQseal Elite system to fortify its presence in the structural heart and endovascular procedures market.
Acquisition Details
Haemonetics acquired Vivasure Medical Limited for \\u20ac100 million with potential additional payments based on performance. This strategic acquisition aims to bolster Haemonetics' product offerings and market position in the medical technology industry.
PerQseal Elite Technology
Vivasure's PerQseal Elite system uses a bioabsorbable patch for large-bore arteriotomies and venotomies, demonstrating positive clinical performance. This technology integration enriches Haemonetics' closure device range and positions the company as a leader in advanced closure technologies.
Commercial Expansion
The acquisition expands Haemonetics' closure device range, strengthening its foothold in the large-bore closure market and advanced closure technologies. By incorporating Vivasure's innovative solutions, Haemonetics aims to drive growth and provide cutting-edge medical solutions to healthcare providers.
- The acquisition enhances Haemonetics' presence in the structural heart and endovascular procedures market, positioning the company as a key player in innovative medical solutions.
- The PerQseal Elite technology offers sutureless, fully absorbable solutions with promising clinical results, potentially driving revenue growth and market differentiation for Haemonetics.
- Haemonetics plans to capitalize on operational synergies resulting from the acquisition to optimize performance and deliver increased value to healthcare providers, potentially improving profitability and market competitiveness.
Haemonetics Corporation's acquisition of Vivasure Medical Limited signifies a significant advancement in its closure device technologies and a strategic strengthening of its market position in the medical technology industry. The integration of Vivasure's PerQseal Elite system is expected to drive growth, enhance product offerings, and solidify Haemonetics' leadership in innovative medical solutions.